WE HAVE GROWN
WE HAVE DEVELOPED
WE ARE SUCCESSFUL



https:// bepartofresearch. nihr.ac.uk/vaccine -studies/

The link below has all the up-to-date information about NIHR approved vaccine studies and where to sign up to hear about them first.



Follow us on Twitter @SFHresearch

Research Snapshot

Your inside look into the world of research at SFH

AUTUMN EDITION 2020



COVID DOGS

Medical Detection Dogs has more than 10 years of research experience, in training bio detection dogs to detect the odour of disease from samples in a controlled environment, and then applying that knowledge to train them to identify changes in human odour caused by certain medical conditions.

The research team are currently recruiting at the COVID drive-through swabbing station, this will be extended to inpatients to ensure the wider community have the chance to take part in this extremely important study.

SIREN Study



Thank you to the huge uptake of staff members to the Siren study at Kings Mill & Newark.

Kings Mill have currently recruited 408

Newark have also recruited 31

This study involves regular antibody testing and COVID swabbing, looking at the short—medium term immunity of staff members within the healthcare setting.

If you would like take part or know more about the study, please call ext. 3990



The research department are passionate about ensuring all patients with COVID19 or are being treated for this are given the opportunity to take part, therefore they have adapted to working a 7 day a week service and assisting whilst on the wards.

REMAP—CAP

Patients admitted to ITU with moderate—severe COVID19 are given the opportunity to receive convelesant plasma on the REMAP-CAP Trial.

This will be extended to include anti-coagulation therapy, high dose Vitamin C & anti-viral medication.

Patients with a poor outcome have been noted to have deranged blood results suggesting hyper-coagulation.

It has been suggested that high doses of vitamin C may be useful to treat infection and the inflammation often seen in sepsis and especially COVID-19. However, there is no clear evidence of benefit for this treatment yet.

RECOVERY



https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third -in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19

You may have seen us out on the wards recruiting to the RECOVERY trial which has found that - Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19.

The RECOVERY trial is ever changing as and when treatments are found to be beneficial to patients hospitalised with COVID 19.

Patients can currently be randomised to Azithromycin +/- Convalescent plasma or Monoclonal Antibodies.

Patients who have deteriorated can be randomised to an additional treatment - Tocilizumab, which is a drug currently used for Rheumatoid Arthritis.

21 3,500 3,000 2,500 1,500 1,000 Apr May Jun Jul Aug Sept Oct Nov Dec Jan Feb Mar

RECRUITMENT TO DATE

ISARIC - 346 REMAP-CAP - 3

Recovery - 98 SIREN - 439

GeNOMICC - 28 COVID DOGS - 162

PAN-COVID - 7

Want to get involved?

Speak to your research champions to find out which clinical trials and studies that are happening in your area now.

sfh-tr.researchandinnovation@nhs.net 01623 622515, extension 3990





